(RTTNews) - Johnson & Johnson (JNJ) reported three-year data showing sustained clinical and endoscopic remission with Tremfya (guselkumab) in adults with moderately to severely active Crohn's disease.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.